3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Breast Neoplasms
5
Recurrence
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Interventions
enzalutamide
3
rucaparib
2
Abiraterone Acetate
2
abiraterone
1
Pluvicto
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Castration Resistant Prostate Cancer
×
rucaparib
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA
NCT04179396
2023-06-29
RAMP
pharmaand GmbH
Phase 1
Completed
8 enrolled
8 charts